Effects of the Cha1 Novel Combination Treatment on Tumor Properties and Immune Response in Triple Negative Breast Cancer

DeIeso-Frechette, Francesca H.


  • Experiments at the Yee lab have shown that Cha1, a combination treatment of Epigallocatechin-3-gallate (EGCG) and 5-aza-2’-deoxycytidine (Decitabine, or DAC), can decrease metastases and tumor growth while increasing immune response in Triple Negative Breast Cancer (TNBC) in xenograft and syngeneic mouse models. TNBC is an aggressive form of breast cancer that, unlike other types of breast cancer, ... read more
This object is in collection Creator department Thesis Type Subject Genre Permanent URL
To Cite:
TARC Citation Guide    EndNote
Detailed Rights